| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Brands | $2.36B | $2.36B | $2.17B | $2.12B | $2.28B | $2.44B | $2.35B | $2.33B |
| Generics | $1.42B | $1.38B | $1.35B | $1.13B | $1.28B | $1.31B | $1.34B | $1.18B |
| Lipitor | $348.40M | $375.60M | $355.90M | $388.00M | $387.90M | $396.10M | $377.30M | $462.00M |
| Norvasc | $161.90M | $168.90M | $166.20M | $172.30M | $182.70M | $179.70M | $175.20M | $210.00M |
| Lyrica ® | $124.30M | $129.90M | $127.00M | $112.60M | $128.10M | $126.50M | $119.80M | $120.60M |
| EpiPen® Auto-Injectors | $115.50M | $123.20M | $73.10M | $96.70M | $136.80M | $157.20M | $79.00M | $101.10M |
| Creon ® | $78.20M | $84.60M | $90.40M | $82.40M | $91.40M | $93.10M | $98.90M | $97.40M |
| Viagra ® | $106.10M | $100.20M | $88.60M | $98.50M | $100.30M | $105.20M | $104.20M | $95.00M |
| Zoloft ® | $58.90M | $60.60M | $58.20M | $60.20M | $61.10M | $66.80M | $66.80M | $72.60M |
| Celebrex ® | $72.20M | $74.10M | $67.10M | $63.40M | $70.00M | $73.30M | $66.20M | $67.10M |
| Yupelri ® | $54.50M | $62.20M | $66.60M | $58.30M | $66.60M | $71.40M | $70.60M | $62.50M |
| Effexor ® | $62.70M | $66.30M | $64.50M | $59.30M | $63.10M | $67.20M | $68.10M | $62.00M |
| Xalabrands | $45.60M | $41.20M | $37.10M | $37.10M | $40.70M | $38.60M | $42.00M | $39.20M |
| Dymista ® | $55.00M | $43.50M | $41.30M | $42.80M | $48.40M | $33.80M | $38.60M | $37.30M |
| Xanax ® | $35.40M | $38.60M | $36.50M | $32.30M | $33.90M | $34.20M | $39.50M | $34.80M |
| Total | $3.80B | $3.75B | $3.53B | $3.25B | $3.58B | $3.76B | $3.70B | $3.52B |